Τίτλος:
Improved glycaemic control with miglitol in inadequately-controlled type
2 diabetics
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Objective: The study compared the long-term efficacy and safety of
miglitol to placebo in Type 2 diabetic outpatients inadequately
controlled on combination therapy of diet, glibenclamide and metformin.
Methods: Type 2 diabetic patients (n = 154) receiving glibenclamide 7-20
mg/day and at least one 500-850 mg tablet metformin per day were
randomized to receive additional miglitol or placebo for 24 weeks,
titrated up stepwise from 25 to 100 mg trice daily. Results: Addition of
miglitol to sulphonylureas and metformin (per protocol analysis)
produced a statistically, significantly greater reduction in HbA(1c)
(-0.55%, P = 0.04) and postprandial glucose (-2.6 mmol/l, P = 0.0009)
from baseline to endpoint than placebo (-0.2% and -0.6 mol/l,
respectively). Reduction in fasting blood glucose was greater with
miglitol than placebo, and there was a possible difference in favor of
miglitol for fasting and postprandial triglyceride levels, but these did
not reach statistical significance. Flatulence and diarrhea were
reported by statistically, significantly more patients receiving
miglitol than placebo, but adverse events overall were reported by only
10% more patients in the miglitol group. No cases of hypoglycaemia were
reported. Conclusions: Miglitol can safely and effectively be added to
long-term combination therapy in people with Type 2 diabetes
inadequately controlled with glibenclamide plus metformin. (C) 2001
Elsevier Science Ireland Ltd. All rights reserved.
Συγγραφείς:
Standl, E
Schernthaner, G
Rybka, J
Hanefeld, M
Raptis,
SA
Naditch, L
Περιοδικό:
Diabetes Research and Clinical Practice
Εκδότης:
Elsevier Ireland Ltd
Λέξεις-κλειδιά:
type 2 diabetes; alpha-glucosidase inhibitor; miglitol; sulphonylurea;
metformin
DOI:
10.1016/S0168-8227(00)00231-X
